{"id":"W4243113348","doi":"10.1200/jco.2017.35.15_suppl.502","title":"Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Tolerability; Clinical endpoint; Gastroenterology; Surgery; Breast cancer; Clinical trial; Cancer; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009069399,0.0009544348,0.001702113,0.0005248457,0.0002715968,0.001263221,0.0009505642,0.00127603,0.005319623],"category_scores_gemma":[0.009211085,0.000424514,0.002781535,0.000835841,0.000286847,0.001130712,0.0007883861,0.00253254,0.0008732778],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008227504,"about_ca_system_score_gemma":0.001166802,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001163165,"about_ca_topic_score_gemma":0.004117912,"domain_scores_codex":[0.9970574,0.001988998,0.0001674694,0.0001991079,0.0004286317,0.0001584486],"domain_scores_gemma":[0.992662,0.003249368,0.00243919,0.0004853577,0.0004738806,0.0006901895],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7212682,0.002692988,0.02536936,0.005305886,0.01835597,0.0003000819,0.0002675967,0.004787769,0.005194574,0.0008145985,0.1079254,0.1077177],"study_design_scores_gemma":[0.5808107,0.0743104,0.2054678,0.001444259,0.03966263,0.001572228,0.0001601239,0.003133709,0.003957949,0.001849664,0.08737302,0.000257547],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.696305,0.07815811,0.007267543,0.008088035,0.002397999,0.005468396,0.177073,0.0005724772,0.02466949],"genre_scores_gemma":[0.7892092,0.012364,0.007662375,0.007999647,0.001453982,0.005555147,0.164901,0.0002077402,0.01064691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009069399,"threshold_uncertainty_score":0.04796416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3334326856360255,"score_gpt":0.5070968932165508,"score_spread":0.1736642075805253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}